Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 431 M
EBIT 2017 11,7 M
Net income 2017 -28,0 M
Finance 2017 223 M
Yield 2017 -
Sales 2018 483 M
EBIT 2018 27,4 M
Net income 2018 -21,1 M
Finance 2018 147 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 9 051,85
EV / Sales2017 13,6x
EV / Sales2018 12,3x
Capitalization 6 078 M
More Financials
Company
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology.It operates its business through the Ionis Core and Akcea Therapeutics segments.The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline... 
Sector
Biotechnology & Medical Research
Calendar
08/24 | 07:00pmPresentation
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ISIS PHARMACEUTICALS, INC.
08/23 IONIS PHARMACEUTICALS INC : Today's Research Reports on Trending Tickers: Ionis ..
08/17 IONIS PHARMACEUTICALS : to Independently Advance Inotersen and -FB-L Rx
08/17 IONIS PHARMACEUTICALS : to Present at Upcoming Investor Conferences
08/16 IONIS PHARMACEUTICALS : GSK pulls out of Ionis deal
08/15 GLAXOSMITHKLINE PLC. (ADR)(NYSE : GSK) Restructuring Takes A Toll on Ionis Pharm..
08/15 IONIS PHARMACEUTICALS : to Independently Advance Inotersen and FB L Rx
08/14 IONIS PHARMACEUTICALS : to file rare disease drug after GSK declines option
08/14 IONIS PHARMACEUTICALS INC. (NASDAQ : IONS) Rallies On Improved Guidance
08/14 BIOTECH MOVERS : Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) and Ionis Pharmac..
08/14 Featured Company News – GlaxoSmithKline Drops Options to Licence Inoter..
More news
Sector news : Biotechnology & Medical Research - NEC
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
2014A resistance as obstacle
More Strategies
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Income Statement Evolution
Consensus
 
Mean consensus HOLD
Number of Analysts 13
Average target price 56,7 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Inside Director
Elizabeth L. Hougen CFO, Principal Accounting Officer & SVP-Finance
Joseph H. Wender Independent Outside Director
Frederick T. Muto Independent Outside Director
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, INC.-6.12%6 078
INCYTE CORPORATION20.56%25 479
QUINTILES IMS HOLDINGS INC22.39%20 512
LONZA GROUP40.29%18 025
CELLTRION, INC.--.--%12 698
ALNYLAM PHARMACEUTICALS, INC.117.47%7 871